MA42157A - Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent - Google Patents
Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalentInfo
- Publication number
- MA42157A MA42157A MA042157A MA42157A MA42157A MA 42157 A MA42157 A MA 42157A MA 042157 A MA042157 A MA 042157A MA 42157 A MA42157 A MA 42157A MA 42157 A MA42157 A MA 42157A
- Authority
- MA
- Morocco
- Prior art keywords
- polynucleotide
- salt
- preparation
- composition
- polynucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Des aspects de la description comprennent des procédés pour la préparation d'un polynucléotide. Dans certains modes de réalisation, le procédé comprend la mise en contact d'une première composition polynucléotidique comprenant: un polynucléotide ayant une séquence de 7 sous-unités nucléosidiques ou plus et au moins deux des sous-unités nucléosidiques sont jointes par une liaison inter-sous-unité thiophosphoramidate n3 '→ p5'; et des produits synthétiques non ciblés et des réactifs; avec un sel de cation multivalent pour précipiter un sel de polynucléotide comprenant au moins un contre-ion de cation multivalent; et séparer le sel polynucléotidique de la première composition polynucléotidique mise en contact pour produire une seconde composition polynucléotidique comprenant le sel polynucléotidique. Dans certains modes de réalisation, le procédé comprend en outre la mise en contact du sel de polynucléotide avec un support de chromatographie en phase inverse; et en éluant à partir du support de chromatographie une troisième composition polynucléotidique comprenant le polynucléotide. L'invention concerne également des compositions comprenant un sel du polynucléotide comprenant au moins un contre-ion de cation multivalent.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562151891P | 2015-04-23 | 2015-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42157A true MA42157A (fr) | 2018-02-28 |
Family
ID=55911083
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042157A MA42157A (fr) | 2015-04-23 | 2016-04-21 | Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent |
MA42569A MA42569B1 (fr) | 2015-04-23 | 2016-04-21 | Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42569A MA42569B1 (fr) | 2015-04-23 | 2016-04-21 | Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent |
Country Status (36)
Country | Link |
---|---|
US (2) | US10745687B2 (fr) |
EP (1) | EP3286203B1 (fr) |
JP (3) | JP2018513127A (fr) |
KR (1) | KR102401252B1 (fr) |
CN (2) | CN113564168A (fr) |
AU (2) | AU2016250576C1 (fr) |
BR (1) | BR112017019627B1 (fr) |
CA (1) | CA2978191C (fr) |
CL (1) | CL2017002314A1 (fr) |
CO (1) | CO2017009217A2 (fr) |
CY (1) | CY1123197T1 (fr) |
DK (1) | DK3286203T3 (fr) |
EA (1) | EA035885B1 (fr) |
ES (1) | ES2798270T3 (fr) |
HK (1) | HK1251234A1 (fr) |
HR (1) | HRP20201218T1 (fr) |
HU (1) | HUE051148T2 (fr) |
IL (1) | IL254222A0 (fr) |
LT (1) | LT3286203T (fr) |
MA (2) | MA42157A (fr) |
MD (1) | MD3286203T2 (fr) |
ME (1) | ME03811B (fr) |
MX (1) | MX2017011642A (fr) |
MY (1) | MY187804A (fr) |
PE (2) | PE20221275A1 (fr) |
PH (1) | PH12017501927A1 (fr) |
PT (1) | PT3286203T (fr) |
RS (1) | RS60645B1 (fr) |
SA (1) | SA517390103B1 (fr) |
SG (2) | SG11201707893RA (fr) |
SI (1) | SI3286203T1 (fr) |
TN (1) | TN2017000411A1 (fr) |
TW (1) | TWI736532B (fr) |
UA (1) | UA124521C2 (fr) |
WO (1) | WO2016172346A1 (fr) |
ZA (1) | ZA201706041B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3286203T1 (sl) | 2015-04-23 | 2020-10-30 | Geron Corporation | Metode priprave polinukleotida, z uporabo sestavkov multivalentne kationske soli |
WO2018111967A1 (fr) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Purification par affinité d'arn |
EP3554556B1 (fr) | 2016-12-19 | 2022-03-09 | Ventana Medical Systems, Inc. | Conjugués de peptides et d'acides nucléiques |
WO2019036683A1 (fr) * | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Procédés analytiques par hplc |
EP3684933A4 (fr) * | 2017-09-22 | 2021-06-23 | The Regents of the University of Colorado, A Body Corporate | Oligonucléotides thiomorpholino pour le traitement de la dystrophie musculaire |
WO2019120635A1 (fr) * | 2017-12-18 | 2019-06-27 | Ventana Medical Systems, Inc. | Conjugués à base d'acide nucléique peptidique |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4046720A (en) | 1974-01-17 | 1977-09-06 | California Institute Of Technology | Crosslinked, porous, polyacrylate beads |
US4678814A (en) | 1981-03-30 | 1987-07-07 | California Institute Of Technology | Polyacrolein microspheres |
US4413070A (en) | 1981-03-30 | 1983-11-01 | California Institute Of Technology | Polyacrolein microspheres |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
DE69120821T2 (de) | 1990-08-31 | 1997-01-23 | Univ Minnesota | Polyethylenglykol-Derivate für Festphasenanwendungen |
US5281701A (en) | 1991-07-12 | 1994-01-25 | Applied Biosystems, Inc. | Process and compounds for RNA synthesis |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
AU704549B2 (en) | 1994-03-18 | 1999-04-29 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
WO1998028442A1 (fr) | 1996-12-20 | 1998-07-02 | Geron Corporation | Procedes de detection et d'inhibition de la telomerase dans l'arn |
US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
US6114519A (en) | 1997-10-15 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Synthesis of sulfurized oligonucleotides |
US6465628B1 (en) | 1999-02-04 | 2002-10-15 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
DE60038495T2 (de) | 1999-09-10 | 2009-04-09 | Geron Corp., Menlo Park | Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung |
JP2002060341A (ja) * | 2000-08-21 | 2002-02-26 | Terumo Corp | 止血剤 |
US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
AU2002245717A1 (en) | 2001-03-23 | 2002-10-08 | Geron Corporation | Oligonucleotide conjugates |
EP3682903A1 (fr) * | 2003-09-09 | 2020-07-22 | Geron Corporation | Oligonucléotides modifiés pour l'inhibition de la télomérase |
US20120329858A1 (en) | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
TW200540180A (en) | 2004-05-28 | 2005-12-16 | Sankyo Co | Telomerase inhibitor ena oligonucleotide |
PT1778711T (pt) | 2004-07-02 | 2017-10-19 | Geron Corp | Síntese de monómeros nucleosídeos 3'-amino protegidos |
WO2007041201A2 (fr) * | 2005-10-03 | 2007-04-12 | Applera Corporation | Compositions, procedes et kits pour l'amplification d'acides nucleiques |
TWI442965B (zh) * | 2006-11-01 | 2014-07-01 | Biogen Idec Inc | 使用低pH及二價陽離子分離生物巨分子的方法 |
JP5775581B2 (ja) * | 2010-08-20 | 2015-09-09 | レプリコール インコーポレーティッド | オリゴヌクレオチドキレート錯体 |
US9106103B2 (en) | 2011-09-23 | 2015-08-11 | Eaton Corporation | Unintteruptible power supply systems and methods employing on-demand energy storage |
US9006630B2 (en) | 2012-01-13 | 2015-04-14 | Altasens, Inc. | Quality of optically black reference pixels in CMOS iSoCs |
AR091065A1 (es) | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
CN110343673B (zh) * | 2012-06-14 | 2024-04-05 | 生命技术公司 | 用于聚合酶链式反应(pcr)的新型组合物、方法和试剂盒 |
UA117116C2 (uk) * | 2012-12-07 | 2018-06-25 | Джерон Корпорейшн | Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм |
JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
SI3286203T1 (sl) | 2015-04-23 | 2020-10-30 | Geron Corporation | Metode priprave polinukleotida, z uporabo sestavkov multivalentne kationske soli |
-
2016
- 2016-04-21 SI SI201630771T patent/SI3286203T1/sl unknown
- 2016-04-21 TW TW105112455A patent/TWI736532B/zh active
- 2016-04-21 SG SG11201707893RA patent/SG11201707893RA/en unknown
- 2016-04-21 MA MA042157A patent/MA42157A/fr unknown
- 2016-04-21 BR BR112017019627-1A patent/BR112017019627B1/pt active IP Right Grant
- 2016-04-21 WO PCT/US2016/028657 patent/WO2016172346A1/fr active Application Filing
- 2016-04-21 MD MDE20180204T patent/MD3286203T2/ro unknown
- 2016-04-21 PT PT167206366T patent/PT3286203T/pt unknown
- 2016-04-21 CA CA2978191A patent/CA2978191C/fr active Active
- 2016-04-21 CN CN202110878917.1A patent/CN113564168A/zh active Pending
- 2016-04-21 TN TNP/2017/000411A patent/TN2017000411A1/en unknown
- 2016-04-21 PE PE2022001164A patent/PE20221275A1/es unknown
- 2016-04-21 HU HUE16720636A patent/HUE051148T2/hu unknown
- 2016-04-21 EA EA201791753A patent/EA035885B1/ru unknown
- 2016-04-21 AU AU2016250576A patent/AU2016250576C1/en active Active
- 2016-04-21 SG SG10201909816P patent/SG10201909816PA/en unknown
- 2016-04-21 PE PE2017001516A patent/PE20171785A1/es unknown
- 2016-04-21 LT LTEP16720636.6T patent/LT3286203T/lt unknown
- 2016-04-21 UA UAA201708890A patent/UA124521C2/uk unknown
- 2016-04-21 CN CN201680014382.0A patent/CN107429247B/zh active Active
- 2016-04-21 US US15/134,740 patent/US10745687B2/en active Active
- 2016-04-21 MA MA42569A patent/MA42569B1/fr unknown
- 2016-04-21 ES ES16720636T patent/ES2798270T3/es active Active
- 2016-04-21 RS RS20200935A patent/RS60645B1/sr unknown
- 2016-04-21 DK DK16720636.6T patent/DK3286203T3/da active
- 2016-04-21 MY MYPI2017703910A patent/MY187804A/en unknown
- 2016-04-21 KR KR1020177025835A patent/KR102401252B1/ko active IP Right Grant
- 2016-04-21 MX MX2017011642A patent/MX2017011642A/es unknown
- 2016-04-21 ME MEP-2020-161A patent/ME03811B/fr unknown
- 2016-04-21 JP JP2017548279A patent/JP2018513127A/ja not_active Withdrawn
- 2016-04-21 EP EP16720636.6A patent/EP3286203B1/fr active Active
-
2017
- 2017-08-30 IL IL254222A patent/IL254222A0/en active IP Right Grant
- 2017-09-05 ZA ZA201706041A patent/ZA201706041B/en unknown
- 2017-09-12 CO CONC2017/0009217A patent/CO2017009217A2/es unknown
- 2017-09-13 CL CL2017002314A patent/CL2017002314A1/es unknown
- 2017-10-04 SA SA517390103A patent/SA517390103B1/ar unknown
- 2017-10-20 PH PH12017501927A patent/PH12017501927A1/en unknown
-
2018
- 2018-08-18 HK HK18110626.1A patent/HK1251234A1/zh unknown
-
2020
- 2020-07-09 CY CY20201100632T patent/CY1123197T1/el unknown
- 2020-07-10 US US16/926,340 patent/US11441144B2/en active Active
- 2020-08-03 HR HRP20201218TT patent/HRP20201218T1/hr unknown
-
2021
- 2021-05-04 AU AU2021202803A patent/AU2021202803A1/en not_active Abandoned
- 2021-07-01 JP JP2021110090A patent/JP2021152079A/ja active Pending
-
2022
- 2022-09-02 JP JP2022140111A patent/JP2022168017A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42157A (fr) | Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent | |
MA35175B1 (fr) | Domaines de liaison du serum deimmunise et leur utilisation pour prolonger le demi-vie du serum | |
WO2018064589A9 (fr) | Dégradation ciblée de protéines à l'aide d'une ubiquitine ligase e3 mutante | |
MA40882B1 (fr) | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf | |
BR112018006562A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, conjugado e uso de um anticorpo | |
NZ737046A (en) | Anti-cgrp antibody formulation | |
EA201791984A1 (ru) | Способы уменьшения уровня fc-содержащих агентов в сыворотке с применением fcrn-антагонистов | |
EA201100300A1 (ru) | Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента | |
NO20084796L (no) | Antagoist anti-CD40 antistoff farmasoytiske smmensetninger | |
WO2010062779A3 (fr) | Adn polymérases modifiées | |
FR3041505B1 (fr) | Composition acide comprenant au moins une phycocyanine stable a ph acide | |
MA40481A (fr) | Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante | |
WO2012059598A3 (fr) | Méthodes de traitement de la polyarthrite rhumatoïde au moyen d'antagonistes d'il-17 | |
WO2013115926A3 (fr) | Conjugués aspartyl-arnt synthétase-fc | |
FR2964618B1 (fr) | Dispositif de solidarisation d'une lampe sur un balai d'essuyage | |
WO2015138394A3 (fr) | Variants hppd et leurs procédés d'utilisation | |
MX2019003890A (es) | Anticuerpos con union reducida a impurezas de proceso. | |
MA40793B1 (fr) | Composition acide a base de leonardite et d'acides amines | |
FR3034430A1 (fr) | Lignee cellulaire surexprimant l'antigene cd303 humain | |
PH12017500967A1 (en) | Selective reduction of cysteine residues in il-17 antibodies | |
FR3045834B1 (fr) | Diluant de reactifs pour immunoessai | |
MA20150436A1 (fr) | Préparation pharmaceutique | |
EA201391605A1 (ru) | Способы очистки вирусов с использованием гельпроникающей хроматографии | |
FR3001729B1 (fr) | Mutants du facteur x | |
MX2020011631A (es) | Ensayo de acetaminofeno. |